<DOC>
	<DOCNO>NCT02527317</DOCNO>
	<brief_summary>This prospective , non-interventional , single arm study , examine doxorubicin cyclophosphamide ( AC ) every 2 week lipegfilgrastim support early breast cancer .</brief_summary>
	<brief_title>Dose Dense Chemotherapy With Lipegfilgrastim Support Early Breast Cancer</brief_title>
	<detailed_description>An important advance use dose dense chemotherapy regimens breast cancer development pegylated form G-CSF ( pegfilgrastim lipegfilgrastim ) , offer convenience single subcutaneous injection , rather multiple daily injection Lipegfilgrastim pegylated long-acting covalent conjugate filgrastim ( G-CSF ) . In pivotal randomized phase III study breast cancer lipegfilgrastim show non-inferior pegfilgrastim . In prospective observational study incidence treatment-related neutropenia follow four cycle dose dense ( every 2 week ) doxorubicin cyclophosphamide ( AC ) lipegfilgrastim support investigate . Data collect 40 consecutive patient treat AC lipegfilgrastim Ireland . The primary objective study determine incidence treatment-related neutropenia follow four cycle dose dense doxorubicin cyclophosphamide ( AC ) lipegfilgrastim support ( 8 week ) . Secondary Objectives 1 . Determine incidence febrile neutropenia 4 cycle ( 8 week ) dose dense AC lipegfilgrastim 2 . Examine incidence treatment-related neutropenia subsequent intravenous cancer therapy 1 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Age ≥ 18 year 2 . Stage IIII Breast Cancer 3 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 ( see ) 4 . Adequate Bone Marrow Function define neutrophil count ≥1.0 platelet count ≥ 100 5 . Planned chemotherapy Dose Dense DoxorubicinCyclophosphamide ( AC ) deem appropriate Consultant Medical Oncologist General Indications Dose Dense AC include : 1 . T3 T4 Tumours 2 . N1 N3 ( Node Positive ) Disease 3 . Human Epidermal Growth Factor Receptor 2 ( HER2 ) Positive Tumours . 4 . Triple Negative Breast Cancer evidence lack expression estrogen receptor ( ER ) , progesterone receptor ( PR ) HER2 1 . Stage IV Breast Cancer 2 . Pregnancy 3 . Previous Chemotherapy Exposure 4 . Prior Exposure GCSF 5 . Known positive HIV Status 6 . Cardiac concurrent illness , investigator 's discretion contraindicate use AC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Early</keyword>
</DOC>